MYB and acute promyelocytic leukemia: Due all-trans retinoic acid (ATRA) appears capable of interrupting the self-regulatory enhancer loop that occurs with fusion genes involving MYB, decreasing the level of oncogenic fusion protein, a phase II clinical trial using this compound in patients with acute promyelocytic leukemia (APL) It was conducted (85).